Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision tag on the study page updated from v3.5.3 to v3.5.4. This reflects a new internal update to the page’s revision history.
    Difference
    0.0%
    Check dated 2026-05-18T13:38:29.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s revision label was updated from version v3.5.0 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-27T08:01:15.000Z thumbnail image
  5. Check
    58 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 on the page.
    Difference
    0.0%
    Check dated 2026-03-22T08:57:14.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-08T01:55:10.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    Plain Language Summary added to the Study Details page. The update also lists recent change dates (2026-02-17, 2026-02, 2026-02-19) alongside the new content.
    Difference
    0.1%
    Check dated 2026-02-21T11:04:49.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.4.1 to v3.4.2; this is a minor metadata update with no user-facing impact. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T08:57:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.